Do you need a prescription for semaglutide? This is how it works

Is Semaglutide Prescription Only?

Yes, all medicines containing semaglutide are prescription-only across the European Union and are authorised centrally by the European Medicines Agency (EMA) or nationally by relevant medicines agencies within the EU. This includes well-known brand names such as Wegovy (weight loss injection), Ozempic (injections for type 2 diabetes), and Rybelsus (oral tablets for type 2 diabetes). These medications contain the same active ingredient but are prescribed for different indications.

Semaglutide is a potent medical treatment that alters biological processes in your body by mimicking the natural hormone GLP-1 to regulate blood sugar and appetite. It requires medical supervision to ensure it is safe for your health and to monitor potential side effects.

Is Semaglutide Available Over the Counter?

No, semaglutide is not available over the counter anywhere in the European Union. You must have a valid prescription from a licensed healthcare professional to purchase it at a pharmacy. Semaglutide may be prescribed either for glycaemic control in type 2 diabetes or, in the case of Wegovy, for chronic weight management in eligible individuals.

Due to high global demand for weight loss medications, a dangerous black market has emerged. Regulatory agencies have issued severe warnings about falsified versions of semaglutide (like fake Ozempic pens) being sold through illegal online pharmacies. These counterfeit drugs can contain dangerous, undeclared substances that pose severe health risks. You should only obtain semaglutide through a legitimate healthcare provider and a certified pharmacy.

Who Qualifies for Semaglutide Based on Body Mass Index?

Treatment eligibility is determined in accordance with regulatory approvals and applicable national clinical guidelines, which may vary between countries. These frameworks focus on managing overweight and treating obesity through a combination of healthy lifestyle changes, medical interventions, and ongoing support. For semaglutide prescribed specifically for weight management (e.g., Wegovy), eligibility is typically based on

• BMI ≥ 30: Classified as living with obesity.

• BMI ≥ 27 with weight-related comorbidities: Overweight with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, dyslipidemia (high cholesterol), or obstructive sleep apnoea.

Final prescribing decisions are always made following an individual medical assessment.

Semaglutide Prescription Requirements from a Healthcare Professional

Before a doctor can issue a prescription, they must conduct a thorough medical evaluation. The requirements usually involve:

1. Health Declaration: A detailed review of your medical history, current medications,  and previous weight loss attempts.
2. Blood Tests: It is not only about being “approved” for treatment, but about establishing a safe medical baseline. Tests such as blood glucose, lipid levels, and liver function markers can indicate both the level of risk and the improvements that occur during treatment.
3. Commitment to Healthy Lifestyle Changes: Semaglutide is not a standalone cure. Clinical guidelines dictate that the medication must be prescribed as an adjunct to a reduced-calorie diet and increased physical activity. The dose is increased gradually to help the body adjust and minimize side effects.

Depending on the formulation prescribed, semaglutide is administered either as a once-weekly subcutaneous injection (e.g., Wegovy) or as a once-daily oral tablet (Rybelsus).

Semaglutide Prescription for Weight Loss Treatment

When discussing a semaglutide prescription for weight loss, it is crucial to differentiate between the available brand names.

Wegovy is the specific version of semaglutide that is approved for chronic weight management in adults with obesity or overweight. In clinical trials, patients using Wegovy (2.4 mg) alongside diet and exercise achieved an average weight loss of 15 to 17% over 68 weeks.

Ozempic and Rybelsus also contain semaglutide but are approved for the treatment of insufficiently controlled type 2 diabetes to improve glycaemic control, as an adjunct to diet and exercise. Ozempic and Rybelsus are not approved for the treatment of obesity. However, in certain cases, physicians may consider so-called off-label use — that is, prescribing outside the formally approved indication — if they determine that the patient has a medical need and may benefit from the treatment.

In such situations, the same medical assessment criteria typically applied to medications approved for weight management are generally used, for example a BMI ≥ 30, or a BMI ≥ 27 in the presence of weight-related comorbidities (such as hypertension, type 2 diabetes, or dyslipidaemia).

Online Doctor Consultations

If you’re considering semaglutide as part of your weight loss journey, online doctor consultations offer a convenient way to access expert advice and support. Through a reputable online doctor service, you can discuss your medical history, lifestyle, and weight loss goals to determine if semaglutide is the right option for you. These digital consultations make it easier to receive ongoing guidance, adjust your treatment plan as needed, and stay motivated throughout your weight loss process.

Always choose an online doctor registered with the appropriate healthcare authorities and experienced in prescribing weight loss medications to ensure you receive safe, medically reviewed care tailored to your needs. At Yazen, our licensed healthcare professionals provide comprehensive assessments and ongoing support to help patients achieve sustainable weight management in a safe and structured way.

How Semaglutide Works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone in your body. It activates GLP-1 receptors in both the brain and digestive system, which helps regulate appetite and food intake. This action reduces hunger and increases feelings of fullness, making it easier to eat less and achieve steady, sustainable weight loss. By slowing down how quickly the stomach empties, semaglutide further helps prevent overeating and supports a gradual reduction in body weight.

Forms and Administration

Depending on the authorised product, semaglutide is available as a once-weekly subcutaneous injection or as a once-daily oral tablet. The treatment typically starts with a lower dose that is gradually increased over several weeks, allowing your body to adjust and helping to minimize side effects such as nausea or other gastrointestinal side effects. Once you reach the maintenance dose, treatment continues according to the prescribed formulation — either weekly injections or daily oral tablets.

Always follow your healthcare professional’s instructions for dosing and administration to ensure the medication is both safe and effective for your weight loss treatment. Semaglutide should be taken alongside a reduced-calorie diet and increased physical activity to maximize results and promote a healthy lifestyle.

Potential Side Effects

As with any prescription medicine, semaglutide can cause side effects, especially when treatment is initiated or after a dose increase. The most common side effects include nausea, vomiting, diarrhea, constipation, headache, fatigue, and indigestion.

It’s essential to keep your healthcare team informed about any side effects you experience so they can help you manage symptoms and adjust your treatment plan if needed. Open communication with your healthcare professional ensures your weight loss journey remains safe and effective.

References

European Medicines Agency (EMA): Wegovy – EPAR Product Information.
https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy

European Medicines Agency (EMA): Ozempic – EPAR Product Information.
https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

NICE (National Institute for Health and Care Excellence): Semaglutide for managing overweight and obesity.
https://www.nice.org.uk/guidance/ta875

European Medicines Agency (EMA): EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens.
https://www.ema.europa.eu/en/news/ema-alerts-eu-patients-healthcare-professionals-reports-falsified-ozempic-pens

European Medicines Agency (EMA): Rybelsus – EPAR Product Information. ://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus

‍